Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being
Completed
- Conditions
- Contraception
- Interventions
- Drug: Other combined oral contraceptivesDrug: EE30-DRSP (Yasmin, BAY86-5131)
- Registration Number
- NCT00988910
- Lead Sponsor
- Bayer
- Brief Summary
The purpose of this study is to evaluate the symptoms and satisfaction for women taking drospirenone (DRSP)-containing combined oral contraceptives in comparison with women taking other kind of combined oral contraceptives.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 632
Inclusion Criteria
- According to the label of the prescribed Combined Oral Contraceptive (COC)
- first Combined Oral Contraceptive use or previous Combined Oral Contraceptive use
- intention to use current COC for 1 year at least
Read More
Exclusion Criteria
- Contraindications listed in the label of the prescribed Combined Oral Contraceptive (COC)
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group 2 Other combined oral contraceptives - Group 1 EE30-DRSP (Yasmin, BAY86-5131) -
- Primary Outcome Measures
Name Time Method Psychophysical well-being evaluated by the Psychological General Well-Being Index (PGWBI) at 12 months Sexual well-being evaluated by the Female Sexual Function Index (FSFI) at 12 months
- Secondary Outcome Measures
Name Time Method